Portal de Periódicos da CAPES

16: Concentration-Controlled Everolimus Versus MMF in De Novo Heart Transplant Patients: Incidence of CMV Infection at 12 Months Post-Transplant in a Randomized Trial

2008; Elsevier BV; Volume: 27; Issue: 2 Linguagem: Inglês

10.1016/j.healun.2007.11.020

1557-3117

T.J. Dengler, Marco Viganò, Carlo Magelli, R. Guillemain, S. Varnous, Gino Gerosa, Alain Poncelet, Johan Vanhaecke, Y. Li, Y. Gezahegen,

Viral Infections and Immunology Research

Everolimus, a proliferation signal inhibitor (PSI), significantly reduces the risk of CMV infection vs. azathioprine after cardiac transplantation. We report here the 12-month incidence of CMV infections in de novo cardiac allograft recipients randomized to concentration-controlled everolimus or MMF with cyclosporine (CsA) and corticosteroids.